| Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma (NCT05578170) | Nanfang Hospital, Southern Medical University | 2022-06-01 |
| Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience (NCT05950737) | Tata Memorial Hospital | 2021-06-01 |
| First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients (NCT04858269) | Wake Forest University Health Sciences | 2021-05-27 |
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) (NCT04801472) | Institut de cancérologie Strasbourg Europe | 2021-05-07 |
| Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. (NCT04445064) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2020-08-14 |
| IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma (NCT03381183) | H. Lee Moffitt Cancer Center and Research Institute | 2019-08-21 |
| Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction (NCT03843515) | Amsterdam UMC, location VUmc | 2019-04-11 |
| Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck (NCT03854032) | Thomas Jefferson University | 2019-04-09 |
| Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma (NCT03618654) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-11-01 |
| Biofeedback Rehabilitation to Improve Speaking and Eating in Public (NCT03650699) | University Health Network, Toronto | 2018-09-28 |
| Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity (NCT03784066) | Universitaire Ziekenhuizen KU Leuven | 2018-08-27 |
| Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation (NCT03510390) | Insel Gruppe AG, University Hospital Bern | 2018-06-13 |
| Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer (NCT02923258) | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2018-04-21 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin (NCT03258554) | National Cancer Institute (NCI) | 2018-04-03 |
| WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer (NCT03028766) | University of Birmingham | 2017-06-22 |
| Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients (NCT03529604) | University of Zagreb | 2016-05-01 |
| Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy (NCT02582008) | Wake Forest University Health Sciences | 2016-01-01 |
| Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer (NCT03053960) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-11-24 |
| Feasibility of CTCs Isolation for Transcriptomes and Genome Wide Associated Analysis in Post-OP High Risk OSCC Patients. (NCT03917524) | Chang Gung Memorial Hospital | 2015-08-01 |
| Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma (NCT02156180) | Queensland Centre of Excellence for Head and Neck Cancer | 2014-04-01 |